HKSE · 1801.HK
Innovent Biologics, Inc.
HK$81.95+HK$0.35 (+0.43%)
Innovent Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 27.28% below the high.
Loading market information…
HKSE · 9926.HK · HKD
Stock price, earnings
Quote as of Oct 30, 2026, 03:28 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Akeso, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.51% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Akeso, Inc.’s next earnings report is currently expected on Mar 31, 2027, with estimated earnings per share of -HK$0.04. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Akeso, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Akeso, Inc. is a biopharmaceutical enterprise dedicated to the discovery, development, manufacturing, and commercialization of therapeutic solutions. The company boasts a diverse pipeline, with a significant focus on oncology. Its cancer-focused treatments include AK104, a PD-1/CTLA-4 bi-specific antibody in development for various malignancies such as cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) adenocarcinoma, hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), nasopharyngeal carcinoma (NPC), clear cell renal cell carcinoma, and other solid tumors. Another bi-specific antibody, AK112, targets PD-1/VEGF and is being developed for solid and gynecological tumors, NSCLC, SCLC, and triple-negative breast cancer (TNBC). Akeso also has several monoclonal antibodies in its oncology portfolio: AK105, a PD-1 monoclonal antibody, is aimed at NSCLC, NPC, relapsed/refractory classic Hodgkin's lymphoma (R/R cHL), HCC, head and neck cancer, thyroid cancer, mesothelioma, thymic cancer, esophageal squamous cell carcinoma (ESCC), urothelial carcinoma (UC), GC, GEJ, cholangiocarcinoma, neuroendocrine tumors, and mismatch repair deficient solid tumors. AK117, a CD47 monoclonal antibody, is being investigated for myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, TNBC, head and neck squamous cell carcinoma (HNSCC), R/R cHL, NPC, NSCLC, as well as general solid tumors and lymphomas. AK119, a CD73 monoclonal antibody, is under development for solid tumors. AK109, a VEGFR-2 monoclonal antibody, targets solid tumors and gastric cancer. Beyond oncology, Akeso is developing treatments for immunological and metabolic conditions: AK120, an IL-4R monoclonal antibody, for moderate-to-severe atopic dermatitis, asthma, and eosinophilic esophagitis. AK101, an IL-12/IL-23 monoclonal antibody, for moderate-to-severe psoriasis and ulcerative colitis. AK111, an IL-17 monoclonal antibody, for moderate-to-severe psoriasis and ankylosing spondylitis. AK102, a PCSK9 monoclonal antibody, designed to treat hypercholesterolemia. Its preclinical pipeline features AK127, a TIGIT monoclonal antibody for solid tumors, and AK115, an NGF monoclonal antibody. Akeso, Inc. collaborates with key partners including Pfizer Pharmaceuticals, AstraZeneca Pharmaceuticals, and the MD Anderson Medical Institute. The company was established in 2012 and operates from its headquarters in Zhongshan, People's Republic of China.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:43 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Aug 30, 2023 |
| HK$3.26 |
| HK$3.98B+18.16% vs estimate |
| Q4 2022 | Mar 16, 2023 | -HK$0.73+42.74% vs estimate | HK$768.22M-3.88% vs estimate |
|---|
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$81.95+HK$0.35 (+0.43%)
Innovent Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 27.28% below the high.
HK$437.80HK$0.00 (0.0%)
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 22.17% below the high.
HK$49.68-HK$0.24 (-0.48%)
Shanghai Henlius Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.96% below the high.
HK$11.46-HK$0.21 (-1.8%)
InnoCare Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 29.26% below the high.
HK$23.42-HK$1.54 (-6.17%)
GenFleet Therapeutics (Shanghai) Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.84% below the high.
HK$9.88+HK$0.03 (+0.3%)
HBM Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 42.15% below the high.
HK$6.34-HK$0.15 (-2.31%)
Alphamab Oncology’s quoted price sits in the lower half of its reported 52-week range, 48.03% below the high.
HK$26.10-HK$0.34 (-1.29%)
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 22.78% below the high.
